Biodexa Pharmaceticals Valuation
| BDRX Stock | 4.98 0.41 8.97% |
At this time, the firm appears to be undervalued. Biodexa Pharmaceticals shows a prevailing Real Value of USD6.39 per share. The current price of the firm is USD4.98. Our model approximates the value of Biodexa Pharmaceticals from analyzing the firm fundamentals such as Return On Equity of -0.97, shares outstanding of 580.84 K, and Operating Margin of (79.31) % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Biodexa Pharmaceticals' valuation include:
Price Book 0.2417 | Enterprise Value -3.2 M | Enterprise Value Ebitda 0.0308 | Price Sales 31.9812 | Enterprise Value Revenue 4.6966 |
Undervalued
Today
Please note that Biodexa Pharmaceticals' price fluctuation is very risky at this time. Calculation of the real value of Biodexa Pharmaceticals is based on 3 months time horizon. Increasing Biodexa Pharmaceticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Biodexa Pharmaceticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Biodexa Stock. However, Biodexa Pharmaceticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.98 | Real 6.39 | Target 8.0 | Hype 5.4 | Naive 4.58 |
The intrinsic value of Biodexa Pharmaceticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Biodexa Pharmaceticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Biodexa Pharmaceticals helps investors to forecast how Biodexa stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Biodexa Pharmaceticals more accurately as focusing exclusively on Biodexa Pharmaceticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Biodexa Pharmaceticals' intrinsic value based on its ongoing forecasts of Biodexa Pharmaceticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Biodexa Pharmaceticals' closest peers.
Biodexa Pharmaceticals Cash |
|
Biodexa Valuation Trend
Analysing the historical paterns of Biodexa Pharmaceticals' enterprise value and its market capitalization is a good way to estimate and gauge the value of Biodexa Pharmaceticals over time and is usually enough for investors to make rational market timing decisions.
Biodexa Pharmaceticals Total Value Analysis
Biodexa Pharmaceticals is currently projected to have valuation of (3.23 M) with market capitalization of 2.65 M, debt of 464 K, and cash on hands of . The negative valuation of Biodexa Pharmaceticals may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Biodexa Pharmaceticals fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(3.23 M) | 2.65 M | 464 K |
Biodexa Pharmaceticals Investor Information
About 38.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.24. Some equities with similar Price to Book (P/B) outperform the market in the long run. Biodexa Pharmaceticals recorded a loss per share of 75.5. The entity last dividend was issued on the 3rd of March 2020. The firm had 1:25 split on the 4th of October 2024. Based on the key indicators related to Biodexa Pharmaceticals' liquidity, profitability, solvency, and operating efficiency, Biodexa Pharmaceticals is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December.Biodexa Pharmaceticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Biodexa Pharmaceticals has an asset utilization ratio of 3.61 percent. This suggests that the Company is making USD0.0361 for each dollar of assets. An increasing asset utilization means that Biodexa Pharmaceticals is more efficient with each dollar of assets it utilizes for everyday operations.Biodexa Pharmaceticals Ownership Allocation
30% of Biodexa Pharmaceticals outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change.Biodexa Pharmaceticals Profitability Analysis
The company reported the previous year's revenue of 381 K. Net Loss for the year was (7.08 M) with loss before overhead, payroll, taxes, and interest of (4.41 M).About Biodexa Pharmaceticals Valuation
Our relative valuation model uses a comparative analysis of Biodexa Pharmaceticals. We calculate exposure to Biodexa Pharmaceticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Biodexa Pharmaceticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -3.7 M | -3.9 M | |
| Pretax Profit Margin | (19.65) | (20.63) | |
| Operating Profit Margin | (21.03) | (22.09) | |
| Net Loss | (18.58) | (19.51) | |
| Gross Profit Margin | (9.67) | (10.16) |
Biodexa Pharmaceticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 31.6 K |
Biodexa Pharmaceticals Current Valuation Indicators
Valuation refers to the process of determining the present value of Biodexa Pharmaceticals and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Biodexa we look at many different elements of the entity such as Biodexa's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Biodexa Pharmaceticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Biodexa Pharmaceticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Biodexa Pharmaceticals' worth.Additional Tools for Biodexa Stock Analysis
When running Biodexa Pharmaceticals' price analysis, check to measure Biodexa Pharmaceticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biodexa Pharmaceticals is operating at the current time. Most of Biodexa Pharmaceticals' value examination focuses on studying past and present price action to predict the probability of Biodexa Pharmaceticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biodexa Pharmaceticals' price. Additionally, you may evaluate how the addition of Biodexa Pharmaceticals to your portfolios can decrease your overall portfolio volatility.